TABLE 1B.
Early response and risk group of ALL patients with and without an SMN as a first event
| Number of patients with SMN | Number of patients without SMN | |
|---|---|---|
| Number of patients | 19 | 1468 |
| Prednisone response | ||
| Good | 11 (58%) | 1079 (74%) |
| Poor | 2 (11%) | 115 (8%) |
| Not available | 6 (32%) | 274 (19%) |
| BM response on day 15 | ||
| M1 | 5 (26%) | 602 (41%) |
| M2 | 3 (16%) | 313 (21%) |
| M3 | 1 (5%) | 117 (8%) |
| not available | 10 (53%) | 436 (30%) |
| Remission status on day 33 | ||
| CR | 13 (68%) | 1161 (79%) |
| No CR | 0 | 30 (2%) |
| Not available | 6 (32%) | 277 (19%) |
| MRD group | ||
| Low‐risk | 2 (11%) | 154 (11%) |
| Intermediate‐risk | 4 (21%) | 358 (24%) |
| High‐risk | 0 | 32 (2%) |
| Not available | 13 (68%) | 924 (63%) |
| Final risk group | ||
| Standard‐risk | 5 (26%) | 516 (35%) |
| Intermediate‐risk | 11 (58%) | 748 (51%) |
| High‐risk | 3 (16%) | 185 (13%) |
| Not available | 0 | 19 (1%) |
| Low‐risk | 16 (84%) | 1263 (86%) |
| High‐risk | 3 (16%) | 186 (13%) |
| Not available | 0 | 19 (1%) |
| Allogeneic HSCT | ||
| Yes | 4 (21%)* | 160 (11%)* |
| No | 15 (79%) | 1308 (89%) |
Abbreviations: BM, bone marrow; CR, complete remission; HSCT, hematopoietic stem cell transplantation; MRD, minimal residual disease; SMN, secondary malignant neoplasm.
*
All four HSCTs among the pts. with an SMN were performed in CR1, while the 160 HSCTs among the pts. without an SMN included HSCTs in CR1 as well as in ≥CR2.